ArrowMark Colorado Holdings LLC Raises Stock Position in Progyny, Inc. $PGNY

ArrowMark Colorado Holdings LLC boosted its position in Progyny, Inc. (NASDAQ:PGNY) by 2.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,931,249 shares of the company’s stock after purchasing an additional 39,666 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 2.24% of Progyny worth $41,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Barclays PLC grew its position in shares of Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the period. Nomura Holdings Inc. purchased a new stake in shares of Progyny in the second quarter worth $9,368,000. Fort Washington Investment Advisors Inc. OH raised its position in shares of Progyny by 33.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after buying an additional 412,395 shares in the last quarter. Finally, CenterBook Partners LP boosted its stake in Progyny by 272.7% during the third quarter. CenterBook Partners LP now owns 424,393 shares of the company’s stock valued at $9,133,000 after buying an additional 310,516 shares during the period. 94.93% of the stock is owned by institutional investors.

Insider Buying and Selling at Progyny

In related news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 7,455 shares of company stock worth $129,515. Company insiders own 9.40% of the company’s stock.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $17.50 on Friday. The firm has a market capitalization of $1.43 billion, a PE ratio of 26.92, a price-to-earnings-growth ratio of 1.17 and a beta of 1.01. Progyny, Inc. has a 52-week low of $16.75 and a 52-week high of $28.75. The firm has a fifty day moving average of $22.30 and a 200 day moving average of $22.74.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. During the same quarter last year, the business posted $0.42 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, sell-side analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

PGNY has been the subject of several recent analyst reports. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Citigroup upgraded Progyny to an “outperform” rating in a research report on Tuesday, January 20th. BTIG Research cut their price objective on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Finally, KeyCorp decreased their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.45.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.